273 related articles for article (PubMed ID: 30501907)
21. Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-κB signaling pathway.
Gao H; Wang J
Mol Med Rep; 2016 Feb; 13(2):1827-32. PubMed ID: 26707811
[TBL] [Abstract][Full Text] [Related]
22. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
23. Toll-like receptors in human multiple myeloma: new insight into inflammation-related pathogenesis.
Abdi J; Garssen J; Redegeld F
Curr Mol Med; 2014 May; 14(4):423-31. PubMed ID: 24730527
[TBL] [Abstract][Full Text] [Related]
24. Towards a new age in the treatment of multiple myeloma.
Piazza FA; Gurrieri C; Trentin L; Semenzato G
Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
[TBL] [Abstract][Full Text] [Related]
25. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
Ito K; Nakazato T; Xian MJ; Yamada T; Hozumi N; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
Cancer Res; 2005 May; 65(10):4417-24. PubMed ID: 15899834
[TBL] [Abstract][Full Text] [Related]
26. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma: lusting for NF-kappaB.
Gilmore TD
Cancer Cell; 2007 Aug; 12(2):95-7. PubMed ID: 17692798
[TBL] [Abstract][Full Text] [Related]
28. [Constitutive NF-kappaB activation in myeloma cells: its underlying mechanism and functional significance].
Otsuyama K
Rinsho Ketsueki; 2009 Jun; 50(6):461-7. PubMed ID: 19571505
[No Abstract] [Full Text] [Related]
29. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
[TBL] [Abstract][Full Text] [Related]
30. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
31. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
Yu L; Li L; Medeiros LJ; Young KH
Blood Rev; 2017 Mar; 31(2):77-92. PubMed ID: 27773462
[TBL] [Abstract][Full Text] [Related]
32. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
33. NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates.
de Castro Barbosa ML; da Conceicao RA; Fraga AGM; Camarinha BD; de Carvalho Silva GC; Lima AGF; Cardoso EA; de Oliveira Freitas Lione V
Anticancer Agents Med Chem; 2017; 17(4):483-490. PubMed ID: 27481554
[TBL] [Abstract][Full Text] [Related]
34. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
35. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
[TBL] [Abstract][Full Text] [Related]
36. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
[TBL] [Abstract][Full Text] [Related]
37. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling.
Zheng P; Guo H; Li G; Han S; Luo F; Liu Y
Biochem Biophys Res Commun; 2015 Mar; 458(2):328-33. PubMed ID: 25656574
[TBL] [Abstract][Full Text] [Related]
38. Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
Horie R
J Clin Exp Hematop; 2013; 53(3):185-95. PubMed ID: 24369220
[TBL] [Abstract][Full Text] [Related]
39. Targeting the NF-κB pathway in cancer therapy.
Erstad DJ; Cusack JC
Surg Oncol Clin N Am; 2013 Oct; 22(4):705-46. PubMed ID: 24012396
[TBL] [Abstract][Full Text] [Related]
40. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Horenstein AL; Bracci C; Morandi F; Malavasi F
Front Immunol; 2019; 10():760. PubMed ID: 31068926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
